Dual cytokine fusion proteins comprising IL-10
The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
1. A dual cytokine fusion protein of formula (I)
NH 2 -(IL-10)-(X 1 )—(Z n )—(X 2 )-(IL-10)-COOH (Formula I);
wherein
“IL-10” is a monomer;
“X 1 ” is a VL or VH region from a first monoclonal antibody;
“X 2 ” is a VH or VL region from the first monoclonal antibody;
wherein when X 1 is a VL, X 2 is a VH or when X 1 is a VH, X 2 is a VL;
wherein the first monoclonal antibody is an anti-Ebola antibody;
wherein the VL and VH from the anti-Ebola antibody comprise three light chain CDRs and three heavy chain CDRs that are engrafted with three light chain CDRs and three heavy chain CDRs from a second monoclonal antibody;
“Z” is a cytokine other than IL-10;
“n” is an integer of 1; and
wherein the IL-10 is SEQ ID No: 16, the second antibody is an anti-PDGFR monoclonal antibody, and Z is IL-2.
2. The fusion protein according to claim 1 , wherein the VH and VL regions comprise a framework region obtained from a human anti-Ebola antibody.
3. The fusion protein according to claim 2 , wherein the framework region from the anti-Ebola antibody is engrafted with the three VH CDRs and three VL CDRs from an anti-HER2 monoclonal antibody.
4. A pharmaceutical composition comprising the dual cytokine fusion protein according to claim 1 , pharmaceutically acceptable buffers, and pharmaceutically acceptable excipients.